Purchase aims to develop therapies for people living with metabolic diseases.
In a deal that could reach up to $1.075 billion pending completion of development and commercial milestones, Novo Nordisk announced its purchase of Inversago Pharma. As part of the deal, Novo Nordisk will acquire Inversago’s lead development asset INV-202, an oral CB1 inverse agonist. This receptor will be used to continue developing therapies for people living with metabolic diseases such as obesity and diabetes.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders,” said Martin Holst Lange, EVP, development, Novo Nordisk, in a company press release. “This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Reference: Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases. GlobeNewswire. August 10, 2023. Accessed August 14, 2023. https://www.globenewswire.com/news-release/2023/08/10/2722413/0/en/Novo-Nordisk-to-acquire-Inversago-Pharma-to-develop-new-therapies-for-people-living-with-obesity-diabetes-and-other-serious-metabolic-diseases.html